Gerald R. Crabtree is the David Korn Professor at Stanford University and an Investigator in the Howard Hughes Medical Institute. He is known for defining the Ca²⁺-calcineurin-NFAT signaling pathway, pioneering the development of synthetic ligands for regulation of biologic processes and discovering chromatin regulatory mechanisms involved in cancer and brain development. He is a founder of Ariad Pharmaceuticals, Amplyx Pharmaceuticals, Foghorn Therapeutics, and Shenandoah Therapeutics (Shenandoah Therapeutics was mentioned in a July 26, 2023 New York Times online article by Gina Kolata).

Crabtree grew up near Wellsburg, West Virginia, earned his B.S. in Chemistry and Mathematics from West Liberty State College and his M.D. from Temple University. While at medical school, he became interested in laboratory research and started to work at Dartmouth College with Allan Munck on the biochemistry of steroid hormones.

In the early 1980s Crabtree worked with Albert J. Fornace Jr. to use early bioinformatics approaches to identify remnants of transposition events (rearrangements) in the human genome and to discover the HNF1 transcription factor. In 1982 Crabtree discovered that one gene could produce more than one protein thereby demonstrating that the coding capability of the genome is larger than expected and breaking the long-held dictum: "one gene; one protein."

In the late 1980s and early '90s, Crabtree mapped the pathways initiated by the antigen receptor on T cells by beginning in the nucleus with the early T cell activation genes like IL-2 and working biochemically toward the cell membrane. These studies led to the discovery of NFAT and the conclusion that membrane signaling by the antigen receptor led to the rapid nuclear entry of this transcription factor and the activation of group of genes like Il-2, gamma interferon and others essential for the immune response. Crabtree, along with Stuart Schreiber, also further defined the Ca²⁺/calcineurin/ NFAT signaling pathway, which carries signals from the cell surface to the nucleus to activate immune response genes. These discoveries resulted in the first understanding of the mechanism of action of the two most commonly used immunosuppressant drugs: cyclosporine and FK506. Crabtree and Schreiber found that these drugs prevent signals originating at the cell membrane from entering the nucleus by blocking the actions of the phosphatase, calcineurin preventing the entry of the NFATc proteins into the nucleus. NFAT proteins activate a large group of genes necessary for the immune response. When these genes are not activated, as occurs with Cyclosporine or FK506 administration, transplant rejection is prevented. The elucidation of the Ca²⁺ - Calcineurin-NFAT signaling pathway and the discovery that it is the target of Cyclosporine and FK506 was covered in the New York Times. Later his laboratory used genetic approaches in mice to show that calcineurin-NFAT signaling plays essential roles in the development of many vertebrate organ systems and its dysregulation is likely to be responsible for many of the phenotypes of Down Syndrome. The understanding of this signaling pathway provided one of the first biochemical bridges from the cell membrane to the nucleus. (see also: Stuart Schreiber).

In 1992, working with Calvin Kuo, then a graduate student in his laboratory, he discovered that the immunosuppressive drug, rapamycin blocked a biochemical pathway leading to protein synthesis in response to membrane cell proliferation signals. This work contributed to the development of rapamycin as a therapeutic for certain human cancers and also played a role in the founding of Ariad Pharmaceuticals in Cambridge, Massachusetts.

In 1993 Crabtree and Stuart Schreiber designed and synthesized the first synthetic ligands to induce proximity of proteins within cells . Crabtree then used these molecules to understand the role of proximity in biologic regulation.  His studies revealed that chemically induced proximity was a fundamental mechanism underlying many aspects of cellular signaling, including receptor activation , kinase function , protein localization , transcription and epigenetic regulation .  He generalized this approach to other types of chemical inducers of proximity (CIPs) including natural molecules involved in plant signaling that have expanded the usefulness of this approach. At present CIPs are being used to probe the function of many signaling pathways and biologic events within cells . This approach has proved useful in rapidly activating and inactivating molecules to allow one to study their function. Crabtree and colleagues Nathan Hathaway and Oli Bell have used induced proximity to make measurements of the dynamics of chromatin regulation in living cells leading to an understanding of the stability of epigenetic changes involved in cellular memory. The development of chemical inducers of proximity by Crabtree and Schreiber was covered in the New York Times and also in Discovery Magazine in 1996. Later, Ariad Pharmaceuticals developed this technology for gene therapy . These discoveries led Steve Crews at Yale to develop PROTACS for the selective degradation of therapeutic targets.

More recently, Crabtree and colleague Nathanael Gray at Stanford have made use of induced proximity to rewire the cancer cell to kill itself using its own mutated driver thereby specifically killing the mutated cancer cell and not normal cells lacking the mutation. This gain-of-function strategy shows promise for avoiding cancer relapse due to secondary cancer drivers and compensation. The development of these molecules (TCIPs for Transcription/epigenetic Chemical Inducers of Proximity) was covered in the New York Times by Gina Kolata.

In the early 1990s Crabtree worked with Paul Khavari, now the Carl J. Herzog Professor of Medicine at Stanford University, to define the mammalian SWI/SNF or BAF complex by purifying and cloning the genes that encode its subunits. Using biochemical and genetic approaches he discovered that the genes that encode its subunits are put together like letters in a word to give a wide variety of different biological meanings. In 2009 he worked with postdoctoral fellow, Andrew Yoo to discover a genetic circuitry controlling the assembly of specialized, brain-specific chromatin regulatory complexes necessary for the development of the mammalian nervous system and demonstrated that recapitulating this circuitry in mammalian cells converts human skin cells to neurons.